William Lewis - Insmed CEO and President and Director
| INSM Stock | USD 24.80 1.38 5.27% |
CEO
Mr. William H. Lewis is a Chairman of the Board, President, Chief Executive Officer of Insmed Inc. From 2011 to 2012, Mr. Lewis was a consultant and acted in that capacity to our Board from June 2012 until September 2012. Mr. Lewis is a former cofounder, in 2005, of Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on developing therapies for rare diseases. At Aegerion, Mr. Lewis served in a series of successively more senior executive administrative and financial roles, notably serving as Chief Financial Officer from March 2005 to August 2009, at which time he became President and served in that role until June 2011. Prior to Aegerion, Mr. Lewis spent more than 10 years working in the United States and Europe in investment banking for JP Morgan, Robertson Stephens, and Wells Fargo. Mr. Lewis serves on the Supervisory Board of uniQure, N.V., a Netherlandsbased gene therapy company, and the Board of Trustees of Oberlin College since 2018.
| Age | 49 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 700 US Highway 202/206, Bridgewater, NJ, United States, 08807 |
| Phone | 908 977 9900 |
| Web | https://www.insmed.com |
Latest Insider Transactions
Lewis holds a Bachelor of Arts degree cum laude from Oberlin College, a MBA from Case Western Reserve University and a Juris Doctor with Honors from Case Western Reserve University. Prior to attending graduate school he worked in the Foreign Service for the U.S. Government.Insmed Management Efficiency
The company has return on total asset (ROA) of (0.285) % which means that it has lost $0.285 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (14.5341) %, meaning that it created substantial loss on money invested by shareholders. Insmed's management efficiency ratios could be used to measure how well Insmed manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of April 2024, Return On Equity is likely to grow to 2.37, while Return On Tangible Assets are likely to drop (0.70). At this time, Insmed's Intangibles To Total Assets are very stable compared to the past year. As of the 19th of April 2024, Debt To Assets is likely to grow to 0.95, though Net Tangible Assets are likely to grow to (127.7 M).Similar Executives
| Showing other executives | CEO Age | ||
| Richard Hamilton | Cerevel Therapeutics Holdings | 51 | |
| Cedric Francois | Apellis Pharmaceuticals | 45 | |
| Jeffrey MD | Harmony Biosciences Holdings | 67 | |
| Helen Torley | Halozyme Therapeutics | 55 | |
| Andrew MD | Akero Therapeutics | 57 | |
| Jan Mikkelsen | Ascendis Pharma AS | 64 | |
| David Schenkein | Agios Pharm | 60 | |
| MRCP B | Halozyme Therapeutics | 61 | |
| Mark Goldsmith | Revolution Medicines | 62 | |
| Jeffrey Albers | Blueprint Medicines Corp | 46 | |
| Sarah Boyce | Avidity BiosciencesInc | 52 | |
| David Campbell | Janux Therapeutics | 64 | |
| MBA Renaud | Cerevel Therapeutics Holdings | 55 | |
| Jeremy MBA | Day One Biopharmaceuticals | 53 | |
| Emil Kakkis | Ultragenyx | 57 | |
| Rostislav Raykov | Fennec Pharmaceuticals | 48 | |
| Kevin Koch | Edgewise Therapeutics | 64 | |
Management Performance
| Return On Equity | -14.53 | ||||
| Return On Asset | -0.28 |
Insmed Inc Leadership Team
Elected by the shareholders, the Insmed's board of directors comprises two types of representatives: Insmed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Insmed. The board's role is to monitor Insmed's management team and ensure that shareholders' interests are well served. Insmed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Insmed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Randy Whitcomb, Lead Independent Director | ||
| Steinar Engelsen, Independent Director | ||
| Andrew Drechsler, CFO | ||
| Paul Streck, Chief Medical Officer | ||
| Blaine Davis, VP, Head of Investor Relations | ||
| Christine Pellizzari, General Counsel and Corporate Secretary | ||
| Mark Quigley, Vice President- Quality Assurance | ||
| John Wise, Head VP | ||
| John Goll, Chief Accounting Officer | ||
| William Lewis, CEO and President and Director | ||
| Myrtle Potter, Director | ||
| John MBA, Chief Officer | ||
| Nicole Schaeffer, Sr. VP of HR and Corporate Services | ||
| Michael Smith, Sr Counsel | ||
| Leo Lee, Director | ||
| Roger MBA, Chief Officer | ||
| Elizabeth Anderson, Director | ||
| Mandy Fahey, Executive Communications | ||
| Donald Hayden, Non-Executive Chairman of the Board | ||
| Sara MBA, Chief Officer | ||
| Anne Fields, Senior Vice President IR Contact Officer | ||
| Alfred Altomari, Independent Director | ||
| Melvin Sharoky, Independent Director | ||
| Laura Perry, IR Contact Officer | ||
| Orlov Schaeffer, Senior Vice President- Human Resource and Corporate Services | ||
| Nicole MBA, Chief Officer | ||
| Walter Perkins, CTO | ||
| Peggy Berry, Vice President- Regulatory Affairs | ||
| MBA JD, CEO President | ||
| Eleanor Barisser, Associate Relations | ||
| Paolo Tombesi, CFO | ||
| MD MBA, Chief Officer | ||
| Roger Adsett, Chief Commercial Officer | ||
| Eugene Sullivan, Chief Medical and Scientific Officer | ||
| John III, VP Officer | ||
| John Soriano, Chief Compliance Officer | ||
| David Brennan, Director | ||
| Michael JD, Chief Secretary | ||
| Randall Whitcomb, Lead Independent Director | ||
| Brian Kaspar, Chief Officer | ||
| David McGirr, Independent Director | ||
| MD FCCP, Chief Officer |
Insmed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Insmed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -14.53 | ||||
| Return On Asset | -0.28 | ||||
| Profit Margin | (2.46) % | ||||
| Operating Margin | (1.94) % | ||||
| Current Valuation | 4.26 B | ||||
| Shares Outstanding | 148.56 M | ||||
| Shares Owned By Insiders | 1.08 % | ||||
| Shares Owned By Institutions | 98.92 % | ||||
| Number Of Shares Shorted | 9.04 M | ||||
| Price To Earning | (8.70) X |
Insmed Investors Sentiment
The influence of Insmed's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Insmed. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Insmed's public news can be used to forecast risks associated with an investment in Insmed. The trend in average sentiment can be used to explain how an investor holding Insmed can time the market purely based on public headlines and social activities around Insmed Inc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Insmed's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Insmed's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Insmed's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Insmed.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Insmed in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Insmed's short interest history, or implied volatility extrapolated from Insmed options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for Insmed Stock analysis
When running Insmed's price analysis, check to measure Insmed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insmed is operating at the current time. Most of Insmed's value examination focuses on studying past and present price action to predict the probability of Insmed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insmed's price. Additionally, you may evaluate how the addition of Insmed to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Commodity Directory Find actively traded commodities issued by global exchanges |
Is Insmed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.34) | Revenue Per Share 2.173 | Quarterly Revenue Growth 0.411 | Return On Assets (0.28) | Return On Equity (14.53) |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.